Abstracts Archive - Page 2572 of 2607 - ACR Meeting Abstracts

Abstract Number: 488 • 2012 ACR/ARHP Annual Meeting
Patient Preferences for Biologic Treatments in Rheumatoid Arthritis
Beenish Nafees¹, Andrew Lloyd¹, Carol L. Gaich², Julie Birt² and Rodney A. Hughes³, ¹Late Phase & Outcomes Research, Oxford Outcomes, Oxford, United Kingdom, ²Global Health Outcomes, Eli Lilly and Company, Indianapolis, IN, ³Rheumatology, St. Peters Hospital, Chertsey Surrey, United Kingdom
Background/Purpose: Patients with rheumatoid arthritis (RA) and their physicians face a range of treatment choices. The treatments that patients receive should be driven partly by…
Abstract Number: 489 • 2012 ACR/ARHP Annual Meeting
The Comparative Effectiveness of Anti-TNF Medications Among Older and Disabled Rheumatoid Arthritis Patients in the U.S. Medicare Population
Huifeng Yun¹, Fenglong Xie², Elizabeth S. Delzell³, Lang Chen⁴, Shuo Yang⁵, Kenneth G. Saag⁶ and Jeffrey R. Curtis⁷, ¹Health Care Organization & Policy, University of Alabama-Birmingham, Birmingham, AL, ²Rheumatology & Immunology, University of Alabama at Birmingham, Birmingham, AL, ³Epidemiology, University of Alabama at Birmingham, Birmingham, AL, ⁴Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁵Clinical Immunology/Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁶Div Clinical Immun & Rheum, Univ of Alabama-Birmingham, Birmingham, AL, ⁷Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Evaluating the real world effectiveness of biologic DMARDs in rheumatoid arthritis (RA) patients using administrative claims data has previously not been feasible due to…
Abstract Number: 450 • 2012 ACR/ARHP Annual Meeting
Late Onset Neutropenia After Rituximab Treatment for Rheumatological Conditions
Gabriel S. Breuer¹, Michael Z. Ehrenfeld², Itzhak Rosner³, Alexandra Balbir-Gurman⁴, Devy Zisman⁵ and Daphna Paran⁶, ¹Rheumatology, Shaare Zedek Medical Center, Jerusalem, Israel, ²Dept of Med C & Rheum Dis Unit, Chaim Sheba Medical Center, Tel HaShomer, Israel, ³Rheumatology, Bnai Zion Medical Center / Technion Faculty of Medicine, Haifa, Israel, ⁴B. Shine Rheumatology Unit, Rambam Health Care Campus, Bruce, Haifa, Israel, ⁵Dept of Internal Medicine, Carmel Medical Center, Haifa, Israel, ⁶Rheumatology, Tel Aviv Sourasky Medical Ctr, Tel Aviv, Israel
Background/Purpose: Rituximab is a monoclonal chimeric antibody targeting the CD20 on the surface of normal and abnormal maturing B cells. Late onset neutropenia (LON) is…
Abstract Number: 451 • 2012 ACR/ARHP Annual Meeting
Pilot Study of Stimulation of the Cholinergic Anti-Inflammatory Pathway with an Implantable Vagus Nerve Stimulation Device in Patients with Rheumatoid Arthritis
Frieda A. Koopman¹, Sanda Miljko², Simeon Grazio³, Sekib Sokolovic⁴, Kevin Tracey⁵, Yaakov Levine⁶, Ralph Zitnik⁶ and Paul-Peter Tak⁷, ¹Division of Clinical Immunology and Rheumatology, Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands, ²University Clinical Hospital, Mostar, Bosnia, ³Clinical Hospital Center Sestre Milosrdnice, Zagreb, Croatia, ⁴Rheumatology, University Clinical Center, Sarajevo, Bosnia, ⁵Feinstein Institute for Medical Research, Manhasset, NY, ⁶SetPoint Medical Corporation, Valencia, CA, ⁷Academic Medical Center / currently also GlaxoSmithKline, Amsterdam, Netherlands
Background/Purpose: The inflammatory reflex regulates innate and adaptive immunity (Andersson O, Tracey K, Annu. Rev. Immunol. 2012; 30:313). Activation of its efferent arm (the Cholinergic…
Abstract Number: 452 • 2012 ACR/ARHP Annual Meeting
Effectiveness and Tolerance Infiltration Intraarticular Corticosteroid According to Dose
Daniele F. Pereira¹, Rita N.V. Furtado², Natalia P. Machado³ and Jamil Natour⁴, ¹Disciplina de Reumatologia, Universidade Federal de São Paulo (UNIFESP), São Paulo, Brazil, ²Rheumatology, Universidade Federal de São Paulo, São Paulo, Brazil, ³Disciplina de Reumatologia, Universidade Federal de São Paulo, São Paulo, Brazil, ⁴Rheumatology Division, Universidade Federal de São Paulo, São Paulo, Brazil
Background/Purpose: The optimal dose of corticosteroid to be used in intraarticular injection is not well established. The objective of this study is to compare the…
Abstract Number: 453 • 2012 ACR/ARHP Annual Meeting
Fish Oil in Rheumatoid Arthritis: A Randomised, Double Blind Trial Comparing High Dose with Low Dose
Susanna Proudman¹, Llew Spargo¹, Cindy Hall¹, Leah McWilliams¹, Anita Lee¹, Maureen Rischmueller², Robert Gibson³, Michael James¹ and Leslie G. Cleland¹, ¹Rheumatology Unit, Royal Adelaide Hospital, Adelaide, Australia, ²Rheumatology Department, Queen Elizabeth Hospital, Adelaide, Australia, ³University of Adelaide, Adelaide, Australia
Background/Purpose: The symptomatic benefit and NSAID-sparing effects of fish oil (FO) in RA are well known but effects on disease outcomes are less well established,…
Abstract Number: 454 • 2012 ACR/ARHP Annual Meeting
Long-Term Efficacy of Tocilizumab Monotherapy in Patients with Rheumatoid Arthritis Previously Methotrexate Naive or Methotrexate Free for 6 Months
Graeme Jones¹, Anthony Sebba², Denise Lepley³, Jenny Devenport⁴, Corrado Bernasconi⁵, Devi Smart⁶, Chiedzo Mpofu⁷ and Juan J. Gomez-Reino⁸, ¹Musculoskeletal, Menzies Research Institute Tasmania, Hobart, Australia, ²University of South Florida, Tampa, FL, ³Medical Affairs Immunology, Genentech, South San Francisco, CA, ⁴Genentech, South San Francisco, CA, ⁵Consultant, Basel, Switzerland, ⁶Roche, Welwyn Garden City, United Kingdom, ⁷Roche, Basel, Switzerland, ⁸Rheumatology, Hospital Clinico Universitario, Santiago, Spain
Background/Purpose: Treatment with tocilizumab (TCZ) monotherapy has been studied in 3 randomized clinical trials: AMBITION,1 ACT-RAY,2 and ADACTA.3 AMBITION1 was the first trial to demonstrate…
Abstract Number: 455 • 2012 ACR/ARHP Annual Meeting
Lack of Additive Benefits of Concomitant Methotrexate Use to Tocilizumab Monotherapy for Rheumatoid Arthritis in Daily Clinical Practice
Keisuke Izumi¹, Yuko Kaneko², Hidekata Yasuoka³, Noriyuki Seta⁴, Hideto Kameda⁵, Masataka Kuwana⁵ and Tsutomu Takeuchi⁶, ¹Division of Rheumatology, Keio University School of Medicine, Tokyo, Japan, ²Dept of Internal Medicine, Keio Univ School of Medicine, Shinjuku-ku, Japan, ³Division of Rheumatology, Department of Internal Medicine, Keio Univ School of Medicine, Tokyo, Japan, ⁴Department of Internal Medicine, Keio university, Tokyo, Japan, ⁵Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, ⁶Keio University School of Medicine, Tokyo, Japan
Background/Purpose: To explore the benefit of concomitant use of methotrexate (MTX) for the effectiveness of TCZ in rheumatoid arthritis (RA) patients in daily clinical practice.…
Abstract Number: 456 • 2012 ACR/ARHP Annual Meeting
Factors Influencing Choice of Rituximab Versus an Alternative Tumor Necrosis Factor Inhibitor Following Tumor Necrosis Factor Inhibitor Failure in Patients with Rheumatoid Arthritis: Sub-Analysis of a Global, Observational Comparative Effectiveness Study
Axel Finckh¹, Jacques-Eric Gottenberg², Chiedzo Mpofu³, William G. Bensen⁴, Andrea Rubbert-Roth⁵, Fedra Irazoque⁶, Victor Martínez Taboada⁷, Carol Chung⁸, Lykke Hinsch-Gylvin³, Clodoveo Ferri⁹ and Paul Emery¹⁰, ¹Department of Internal Medicine, University Hospital of Geneva, Geneva, Switzerland, ²Strasbourg University Hospital, Strasbourg, France, ³F Hoffmann-La Roche Ltd, Basel, Switzerland, ⁴Department of Medicine, Division of Rheumatology, Clinical Professor, McMaster University, Hamilton, ON, Canada, ⁵Internal Medicine I, University of Cologne, Cologne, Germany, ⁶Servicio de Reumatología, Hospital Angeles Mocel, Mexico City, Mexico, ⁷Rheumatology Department, Hospital Universitario Marqués de Valdecilla, Santander, Spain, ⁸Genentech Inc., South San Francisco, CA, ⁹Department of Internal Medicine, University of Modena and Reggio Emilia, Modena, Italy, ¹⁰Division of Rheumatic & Musculoskeletal Disease, University of Leeds, Leeds, United Kingdom
Background/Purpose: SWITCH-RA is a global, observational study evaluating the effectiveness of switching to an alternative TNFi or rituximab (RTX) following initial TNFi failure in patients…
Abstract Number: 457 • 2012 ACR/ARHP Annual Meeting
Biologic Disease-Modifying Anti-Rheumatic Drugs and the Risk of Non-Vertebral Osteoporotic Fractures in Patients with Rheumatoid Arthritis Aged 50 Years and Over
Jean-Pascal Roussy¹, Louis Bessette², Sasha Bernatsky³, Elham Rahme⁴ and Jean Lachaine¹, ¹Faculty of Pharmacy, University of Montreal, Montreal, QC, Canada, ²Centre Hospitalier Universitaire de Québec, pavillon CHUL, Sainte-Foy, QC, Canada, ³Clinical Epidemiology, Research Institute of the McGill University Health Centre, McGill University, Montreal, QC, Canada, ⁴Division of Clinical Epidemiology, Research Institute of the McGill University Health Centre, McGill University, Montreal, QC, Canada
Background/Purpose: Chronic inflammation in rheumatoid arthritis (RA) may interfere with bone remodelling. Inflammation mediators such as TNF-α stimulate osteoclast formation which favors bone destruction. Small…
Abstract Number: 458 • 2012 ACR/ARHP Annual Meeting
Better Retention RATE At 5 YEARS of ANTI-TNF Agents USED in Conjonction with Methotrexate Over Time in Patients with Rheumatoid Arthritis: REAL-Life DATA From Rhumadata Computarized Database
Denis Choquette¹, Diane Sauvageau², Boulos Haraoui² and Jean-Pierre Raynauld², ¹Rheumatology, Institut de Rhumatologie De Montréal, Montreal, QC, Canada, ²Rheumatology, Institut de Rhumatologie de Montréal, Montreal, QC, Canada
Background/Purpose: Anti-TNF agents have been in used in Canada for the last ten years. Although a vast body of clinical experience has been accumulated since…
Abstract Number: 459 • 2012 ACR/ARHP Annual Meeting
Long-Term Safety of Rituximab: 10-Year Follow-up in the Rheumatoid Arthritis Global Clinical Trial Program
Ronald F. van Vollenhoven¹, Paul Emery², Clifton O. Bingham III³, Edward Keystone⁴, Roy Fleischmann⁵, Daniel Furst⁶, Nicola Tyson⁷, Abdul Mehbob⁸ and Patrica B. Lehane⁷, ¹Karolinska University Hospital, Stockholm, Sweden, ²Division of Rheumatic & Musculoskeletal Disease, University of Leeds, Leeds, United Kingdom, ³Department of Medicine, Johns Hopkins University, Baltimore, MD, ⁴The Rebecca MacDonald Centre for Arthritis and Autoimmunity, Mount Sinai Hospital, Toronto, ON, Canada, ⁵Rheumatology, University of Texas Southwestern Medical Center and Metroplex Clinical Research Center, Dallas, TX, ⁶Div of Rheumatology, UCLA Medical School, Los Angeles, CA, ⁷Roche Products Limited, Welwyn Garden City, United Kingdom, ⁸Roche Products Ltd., Welwyn Garden City, United Kingdom
Background/Purpose: This analysis evaluated the long-term safety of rituximab (RTX) in RA patients (pts) in a global clinical trial program. Methods: Pooled observed case analysis…
Abstract Number: 460 • 2012 ACR/ARHP Annual Meeting
Real-World Efficacy and Safety of Abatacept Treatment for Rheumatoid Arthritis: 12-Month Interim Analysis of the Action Study
H. Nüßlein¹, R. Alten², M. Galeazzi³, H. M. Lorenz⁴, Dimitrios Boumpas⁵, M. T. Nurmohamed⁶, W. Bensen⁷, Gerd Burmester⁸, H.-H. Peter⁹, F. Rainer¹⁰, Karel Pavelka¹¹, M. Chartier¹², C. Poncet¹³, C. Rauch¹⁴ and M. Le Bars¹⁵, ¹University Erlangen, Nürnberg, Germany, ²Schlosspark-Klinik, University Medicine, Berlin, Germany, ³University of Siena, Siena, Italy, ⁴University Hospital Heidelberg, Heidelberg, Germany, ⁵Panepistimio Kritis, Rethymnon, Greece, ⁶VU University Medical Center/Jan van Bremen Research Institute, Amsterdam, Netherlands, ⁷St. Joseph's Hospital and McMaster University, Hamilton, ON, Canada, ⁸Charité-Universitätsmedizin, Berlin, Germany, ⁹University Medical Center Freiburg, Freiburg, Germany, ¹⁰Hospital Barmherzige Brueder, Graz, Austria, ¹¹Institute of Rheumatology, Prague, Czech Republic, ¹²Chiltern International, Neuilly, France, ¹³Docs International, Sévres, France, ¹⁴Bristol-Myers Squibb, Munich, Germany, ¹⁵Bristol-Myers Squibb, Rueil Malmaison, France
Background/Purpose: Randomized controlled trials (RCTs) of abatacept (ABA) in patients (pts) with RA have demonstrated sustained, long-term efficacy, high pt retention, and consistent safety.1 Data…
Abstract Number: 461 • 2012 ACR/ARHP Annual Meeting
Patterns of Tocilizumab Use, and Dosing Among Patients with Rheumatoid Arthritis in the Clinical Practice. Preliminary Analyses of ACT-Life Study
J.V. Tovar Beltrán¹, M.A. Guzmán Úbeda², I. Mateo Bernardo³, Rosario García-Vicuña⁴, M. Rodríguez-Gómez⁵, M. Belmonte-Serrano⁶, C. Marras⁷, E. Loza Cortina⁸, E. Pérez Pampin⁹, V. Vila Fayos¹⁰, A.B. Romero Silva¹¹ and A. Balsa¹², ¹Hospital General Universitario de Elche, Alicante, Spain, ²Hospital Universitario Virgen de las Nieves, Granada, Spain, ³Hospital Universitario 12 de Octubre, Madrid, Spain, ⁴Hospital Universitario La Princesa, Madrid, Spain, ⁵Complejo Hospitalario Universitario de Ourense, Ourense, Spain, ⁶Hospital General de Castellón, Castellón, Spain, ⁷Hospital Universitario Virgen de la Arrixaca, Murcia, Spain, ⁸Hospital de Navarra, Navarra, Spain, ⁹Complejo Hospitalario Universitario de Santiago, Santiago de Compostela, Spain, ¹⁰Hospital Comarcal de Vinaroz, Castellón, Spain, ¹¹Roche Farma, Madrid, Spain, ¹²Rheumatology, Hospital La Paz, Madrid, Spain
Background/Purpose: Currently, the available evidence about tocilizumab (TCZ) use for the treatment of rheumatoid arthritis (RA) in daily clinical practice is scarce. This study was…
Abstract Number: 462 • 2012 ACR/ARHP Annual Meeting
Subcutaneous Abatacept: Long-Term Data From the Acquire Trial
M. C. Genovese¹, C. Pacheco-Tena², A. Covarrubias³, Gustavo Leon⁴, E. Mysler⁵, M. Keiserman⁶, R. Valente⁷, P. Nash⁸, J. A. Simon-Campos⁹, J. Box¹⁰, C. Legerton III¹¹, E. Nasonov¹², P. Durez¹³, I. Delaet¹⁴ and R. Alten¹⁵, ¹Stanford University, Palo Alto, CA, ²Universidad Autónoma de Chihuahua, Chihuahua, Mexico, ³Centro Medico De Las Americas, Merida, Mexico, ⁴Instituto De Ginecologia Y Reproduccion, Lima, Peru, ⁵Organización Médica de Investigación, Buenos Aires, Argentina, ⁶Pontificial Catholic University School of Medicine, Porto Alegre, Brazil, ⁷Arthritis Center of Nebraska, Lincoln, NE, ⁸Rheumatology Research Unit, Nambour Hospital, Sunshine Coast and Department of Medicine, University of Queensland, Queensland, Australia, ⁹Centro De Especialidades Médicas/Universidad Marista, Merida, Mexico, ¹⁰Carolina Bone and Joint, Charlotte, NC, ¹¹Low Country Rheumatology, Charleston, SC, ¹²Institute of Rheumatology, Moscow, Russia, ¹³Université Catholique de Louvain, Brussels, Belgium, ¹⁴Bristol-Myers Squibb, Princeton, NJ, ¹⁵Schlosspark-Klinik, University Medicine, Berlin, Germany
Background/Purpose: The Abatacept (ABA) Comparison of Sub[QU]cutaneous (SC) versus Intravenous (IV) in Inadequate Responders to MethotrexatE (MTX) (ACQUIRE) study showed comparable efficacy and safety of…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].